Accustem Sciences Inc. (ACUT)
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Accustem Sciences Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 13, 2026 | 0.1260 | 0.1260 | 0.1180 | 0.1180 | 610 |
| Nov 12, 2026 | 0.1300 | 0.1300 | 0.1300 | 0.1300 | 1,581 |
| Nov 11, 2026 | 0.1369 | 0.1369 | 0.1369 | 0.1369 | 125 |
| Nov 5, 2026 | 0.1300 | 0.1300 | 0.1300 | 0.1300 | 309 |
| Nov 4, 2026 | 0.1502 | 0.1502 | 0.1300 | 0.1300 | 1,250 |
| Nov 3, 2026 | 0.1429 | 0.1429 | 0.1429 | 0.1429 | 630 |
| Oct 29, 2026 | 0.1300 | 0.1300 | 0.1300 | 0.1300 | 471 |
| Oct 27, 2026 | 0.1360 | 0.1500 | 0.1360 | 0.1500 | 5,110 |
| Oct 26, 2026 | 0.1550 | 0.1600 | 0.1549 | 0.1549 | 16,997 |
| Oct 22, 2026 | 0.1336 | 0.1336 | 0.1336 | 0.1336 | 356 |
| Oct 8, 2026 | 0.1599 | 0.1599 | 0.1474 | 0.1474 | 12,826 |
| Oct 7, 2026 | 0.1500 | 0.1500 | 0.1500 | 0.1500 | 1,584 |
| Oct 6, 2026 | 0.1500 | 0.1500 | 0.1400 | 0.1400 | 284 |
| Oct 5, 2026 | 0.1350 | 0.1350 | 0.1350 | 0.1350 | 1,070 |
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Director | Purchase | 2.0K | $2.0K | Jun 13, 2025 | |
| Director | Purchase | 400 | $440 | Jun 13, 2025 | |
| Director | Purchase | 9.0K | $7.5K | Jun 12, 2025 | |
| Director | Purchase | 28.2K | $11.0K | Jun 11, 2025 | |
| Director | Purchase | 3.0K | $2.0K | Apr 9, 2025 | |
| Director | Purchase | 35.0K | $23.3K | Apr 8, 2025 |
Insiders
- CERRONE GABRIELE MDirector
AccuStem Sciences, Inc. operates as a life science firm committed to improving the outlook for individuals battling cancer.
Its primary innovation is the StemPrintER technology, an advanced multi-gene prognostic assay designed to predict the likelihood of recurrence for patients with Endocrine receptor-positive /HER2- breast cancer.
The company also offers Spare, a related diagnostic tool that expands upon StemPrintER by incorporating two additional clinical markers. AccuStem Sciences, Inc. is based in New York, New York.
No 13F filer reports a position yet. 13F reports are quarterly and are filed up to 45 days after the quarter ends.
30d Avg
2.74K
60d Avg
2.66K
90d Avg
6.09K
Signal8's dilution snapshot of ACUT as of Jun 30, 2026 records 1 outstanding warrant series, from SEC filings. Accustem Sciences Inc. (OTC: ACUT) traded at $0.1180 on Nov 13, 2026, down 9.23% from the previous close of $0.1300. 52-week range: $0.1170 to $0.9979. The company is in the Healthcare sector (Biotechnology).